Abstract
Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interaction of its ligand (PD-L1), restoring the immune response of T cells, and enhancing the recognition of tumor cells by the immune system. Pulmonary carcinosarcoma is an uncommon but highly aggressive tumor type with a poor prognosis. We described a case of pulmonary carcinosarcoma, with the positive expression of PD-L1, obtained a significant benefit from Nivolumab treatment in a 64-year-old Chinese man, which give us a clue that patients with pulmonary carcinosarcoma may benefit fromanti-PD-1 immunotherapy.
Highlights
Pulmonary carcinosarcoma is a rare type of tumor with a characteristic of strong invasiveness, accounted for 0.1% of all malignant lung tumors [1]
The programmed death-1 (PD-1) is expressed in cytotoxic T cells and T-regulatory cells activated in response to inflammation or infection in peripheral tissues [4]
We first reported a case of a 64-year-old Chinese man, diagnosed as pulmonary carcinosarcoma, with the positive expression of programmed death ligand-1 (PD-L1), obtained a significant benefit from Nivolumab treatment
Summary
Pulmonary carcinosarcoma is a rare type of tumor with a characteristic of strong invasiveness, accounted for 0.1% of all malignant lung tumors [1]. It is defined as malignancy, composed of a mixture of carcinoma and sarcoma elements by the World Health Organization (WHO). We first reported a case of a 64-year-old Chinese man, diagnosed as pulmonary carcinosarcoma, with the positive expression of PD-L1, obtained a significant benefit from Nivolumab treatment. After the consultation with the Cancer Hospital of Chinese Academy of Medical, under the microscope can we see poorly differentiated sarcomatoid-like spindle cancer cells (Figure 1), so it was diagnosed as pulmonary carcinosarcoma. The progress-free survival (PFS) time of this patient has not been reached
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
